Literature DB >> 27698402

Tamoxifen metabolism in breast cancer treatment: Taking the focus off the CYP2D6 gene.

A Novillo1, A Romero-Lorca1, M Gaibar1, M Rubio1, A Fernández-Santander1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27698402     DOI： 10.1038/tpj.2016.73

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN： 1470-269X            Impact factor:   3.550


× No keyword cloud information.
  15 in total

Review 1.  Pharmacogenetics of CYP2D6 and tamoxifen therapy: Light at the end of the tunnel?

Authors:  M Del Re; V Citi; S Crucitta; E Rofi; F Belcari; R H van Schaik; R Danesi
Journal:  Pharmacol Res       Date:  2016-04-08       Impact factor: 7.658

2.  Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.

Authors:  L Madlensky; L Natarajan; S Tchu; M Pu; J Mortimer; S W Flatt; D M Nikoloff; G Hillman; M R Fontecha; H J Lawrence; B A Parker; A H B Wu; J P Pierce
Journal:  Clin Pharmacol Ther       Date:  2011-03-23       Impact factor: 6.875

Review 3.  Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping.

Authors:  Lisette Binkhorst; Ron H J Mathijssen; Agnes Jager; Teun van Gelder
Journal:  Cancer Treat Rev       Date:  2015-01-14       Impact factor: 12.111

4.  Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer.

Authors:  Hyeong-Seok Lim; Han Ju Lee; Keun Seok Lee; Eun Sook Lee; In-Jin Jang; Jungsil Ro
Journal:  J Clin Oncol       Date:  2007-09-01       Impact factor: 44.544

5.  CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy.

Authors:  Wendy A Teft; Inna Y Gong; Brian Dingle; Kylea Potvin; Jawaid Younus; Theodore A Vandenberg; Muriel Brackstone; Francisco E Perera; Yun-Hee Choi; Guangyong Zou; Robin M Legan; Rommel G Tirona; Richard B Kim
Journal:  Breast Cancer Res Treat       Date:  2013-04-12       Impact factor: 4.872

6.  Pharmacogenetics of UGT1A4, UGT2B7 and UGT2B15 and Their Influence on Tamoxifen Disposition in Asian Breast Cancer Patients.

Authors:  Natalia Sutiman; Joanne Siok Liu Lim; Thomas E Muerdter; Onkar Singh; Yin Bun Cheung; Raymond Chee Hui Ng; Yoon Sim Yap; Nan Soon Wong; Peter Cher Siang Ang; Rebecca Dent; Werner Schroth; Matthias Schwab; Chiea Chuen Khor; Balram Chowbay
Journal:  Clin Pharmacokinet       Date:  2016-10       Impact factor: 6.447

7.  Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen.

Authors:  Lisette Binkhorst; Ron H J Mathijssen; Myrthe P P van Herk-Sukel; Marjolein Bannink; Agnes Jager; Erik A C Wiemer; Teun van Gelder
Journal:  Breast Cancer Res Treat       Date:  2013-06-13       Impact factor: 4.872

8.  Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring-The TADE Study.

Authors:  Peter Fox; Rosemary L Balleine; Clara Lee; Bo Gao; Bavanthi Balakrishnar; Alexander M Menzies; Shang Heng Yeap; Sayed Sahanawaz Ali; Val Gebski; Pamela Provan; Sally Coulter; Christopher Liddle; Rina Hui; Richard Kefford; Jodi Lynch; Mark Wong; Nicholas Wilcken; Howard Gurney
Journal:  Clin Cancer Res       Date:  2016-02-04       Impact factor: 12.531

9.  Impacts of the Glucuronidase Genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on Tamoxifen Metabolism in Breast Cancer Patients.

Authors:  Alicia Romero-Lorca; Apolonia Novillo; María Gaibar; Fernando Bandrés; Ana Fernández-Santander
Journal:  PLoS One       Date:  2015-07-15       Impact factor: 3.240

10.  Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen.

Authors:  Mitch Dowsett; Jack Cuzick; Jim Ingle; Alan Coates; John Forbes; Judith Bliss; Marc Buyse; Michael Baum; Aman Buzdar; Marco Colleoni; Charles Coombes; Claire Snowdon; Michael Gnant; Raimund Jakesz; Manfred Kaufmann; Francesco Boccardo; Jon Godwin; Christina Davies; Richard Peto
Journal:  J Clin Oncol       Date:  2009-11-30       Impact factor: 44.544
View more
  3 in total

Review 1.  Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen.

Authors:  Theodore J Wigle; Laura E Jansen; Wendy A Teft; Richard B Kim
Journal:  J Pers Med       Date:  2017-12-13

2.  The effect of CYP2D6 *10 polymorphism on adjuvant tamoxifen in Asian breast cancer patients: a meta-analysis.

Authors:  Junjun Lu; He Li; Peng Guo; Rui Shen; Yingbin Luo; Qiao Ge; Wenfei Shi; Yan Li; Weikang Zhu
Journal:  Onco Targets Ther       Date:  2017-11-13       Impact factor: 4.147

3.  Pharmacogenetics of ugt genes in North African populations.

Authors:  M Gaibar; A Novillo; A Romero-Lorca; M E Esteban; A Fernández-Santander
Journal:  Pharmacogenomics J       Date:  2018-07-31       Impact factor: 3.550
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.